Last reviewed · How we verify
Incobotulinum Toxin A
At a glance
| Generic name | Incobotulinum Toxin A |
|---|---|
| Also known as | Xeomin |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction (PHASE2)
- The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial (PHASE2)
- A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles (EARLY_PHASE1)
- Clinical Effects of Incobotulinum Toxin vs Corticosteroid in Plantar Fascitis (PHASE1)
- Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia (PHASE2)
- Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand (PHASE2)
- Outcomes of Bilateral Temporomandibular Joint Arthroscopy and the Role of a Second Intervention - Timings and Results (NA)
- Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Incobotulinum Toxin A CI brief — competitive landscape report
- Incobotulinum Toxin A updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI